MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Actinium Pharmaceuticals Inc

Closed

1.43

Overview

Share price change

24h

Current

Min

1.43

Max

1.45

Key metrics

By Trading Economics

Income

-9.3M

-16M

Employees

31

EBITDA

-9.3M

-17M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+316.67% upside

Dividends

By Dow Jones

Next Earnings

1 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-4.7M

44M

Previous open

1.43

Previous close

1.43

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

4 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 Jul 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Received All Required Authorizations

4 Jul 2025, 15:48 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 Jul 2025, 15:46 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 Jul 2025, 14:30 UTC

Acquisitions, Mergers, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 Jul 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 Jul 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 Jul 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 Jul 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 Jul 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 Jul 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 Jul 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 Jul 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 Jul 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 Jul 2025, 12:02 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

316.67% upside

12 Months Forecast

Average 6 USD  316.67%

High 9 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.